Veradermics, Incorporated (MANE)

Veradermics, Incorporated is a clinical-stage biopharmaceutical company developing treatments for hair loss. Its lead program, VDPHL01, is an oral, non-hormonal, extended-release formulation of minoxidil designed specifically for treating pattern hair loss.

The company is studying its product candidate in men and women with androgenetic alopecia, the most common form of hair loss, with the aim of providing a once-daily pill that delivers the hair-growth effects of minoxidil with a formulation tailored for this use. It focuses on dermatology and aesthetic conditions with large patient populations and limited approved therapies.

Veradermics is based in New Haven, Connecticut, and its common stock trades on the New York Stock Exchange under the ticker MANE.